Adverse events
| IST continuation (N=48) | IST discontinuation (N=48) | All patients (N=96) | ||
| Death | 0 | 0 | 0 | |
| Renal adverse events | 14 | 18 | 32 | |
| Serum creatinine +20% | 14 | 16 | 30 | |
| Serum creatinine +50% | 0 | 2 | 2 | |
| End-stage kidney disease | 0 | 0 | 0 | |
| Infections | 19 | 14 | 33 | |
| Severe | 1 | 3 | 4 | |
| Appendicitis | 0 | 1 | 1 | |
| Malaria | 0 | 1 | 1 | |
| Zoster | 1 | 1 | 2 | |
| Other | 18 | 11 | 29 | |
| Lower urinary tract | 6 | 4 | 10 | |
| Upper respiratory tract | 4 | 4 | 8 | |
| Ear, nose, and throat | 2 | 1 | 3 | |
| Erysipelas | 1 | 1 | 2 | |
| Dermatomycosis | 2 | 0 | 2 | |
| Cervical human papillomavirus | 2 | 1 | 3 | |
| Warts | 1 | 0 | 1 | |
| Haematological | 41 | 48 | 89 | |
| Myelodysplastic syndrome | 1 | 0 | 1 | |
| Hypereosinophilia | 1 | 0 | 1 | |
| Haematoma | 0 | 1 | 1 | |
| Anaemia with Hb <10 g/dL | 5 | 2 | 7 | |
| Anaemia with Hb <8 g/dL | 1 | 0 | 1 | |
| Leucopenia <4 G/L | 16 | 17 | 33 | |
| Leucopenia <3 G/L | 0 | 4 | 4 | |
| Neutropenia <1.5 G/L | 3 | 7 | 10 | |
| Neutropenia <1 G/L | 0 | 1 | 1 | |
| Lymphopenia <1 G/L | 12 | 16 | 28 | |
| Lymphopenia <0.5 G/L | 1 | 0 | 1 | |
| Thrombopenia <100 G/L | 1 | 0 | 1 | |
| Other | 3 | 6 | 9 | |
| Cataract | 1 | 1 | 2 | |
| Alopecia | 0 | 2 | 2 | |
| Rash unrelated to SLE | 1 | 0 | 1 | |
| New-onset hypertension | 1 | 0 | 1 | |
| Obstructive sleep apnoea | 0 | 1 | 1 | |
| Unexplained chest pain | 0 | 1 | 1 | |
| Unexplained transient dyspnoea | 0 | 1 | 1 | |
Hb, haemoglobin; IST, immunosuppressive therapy; SLE, systemic lupus erythematosus.